Multiply Labs raises $75M for drug manufacturing robots

Multiply Labs announced a $75 million Series B, led by NantWorks, taking total funding above $100 million, according to its October 6 announcement. Its robotic clusters automate biologics manufacturing, and the company says pharmaceutical customers own and operate the systems rather than outsource production to Multiply Labs. The new capital will support manufacturing capacity, product development and engineering, regulatory and commercial teams. For drugmakers, financing expands the supplier’s resources; it does not replace process qualification or outcome evidence—the distinction in our Enveda analysis of capital versus clinical execution.